A series of native and chemically derivatized lactoferrins (Lfs) purified from milk and colostrum were assayed in vitro for their anti-HIV and anti-HCMV-cytopathic effects in MT4 cells and fibroblasts respectively. All Lfs from bovine and human milk or colostrum were able to completely block HCMV replication as well as inhibited HIV-1 induced cytopathic effects.
Through acylation of the amino function of the lysine residues in Lf, using anhydrides of succinic acid or cis-aconitic acid, negatively charged Lf derivatives were obtained that all showed a strong antiviral activity against the HIV-1 in vitro. Acylated-Lf exhibited a 4-fold stronger antiviral effect on HIV-1 than the parent compound but the activity on HCMV was abolished.
Peptide scanning studies indicated that the native Lf as well as acylated Lf strongly bind to the V3 domain of the HIV envelope protein gp120, with Kd values in the same concentration range as the in vitro IC50. Therefore, shielding of this domain, resulting in inhibition of the virus-cell fusion and entry of the virus in MT4 cells is the likely mechanism underlying the anti-HIV activity.
In contrast, addition of positive charges to Lf through amination of the proteins resulted in an increased anti-HCMV activity and a loss of anti-HIV activity, with antianti-HCMV IC50, values in the low micromolar concentration range. The N-terminal portion of Lf appeared essential to this anti-HCMV effect. The specific distribution of positively and negatively charged domains in the molecule appears to be important in both the anti-HIV and anti-HCMV effects.
KeywordsHuman Serum Albumin Antiviral Activity Succinic Anhydride HCMV Infection HCMV Replication
Unable to display preview. Download preview PDF.
- 1.Plummer G: Cytomegaloviruses of man and animals. Prog Med Virol 1973; 9: 302–340.Google Scholar
- 6.Bowden RA: Antivirals for cytomegalovirus. In: Multidisciplinary approach to understanding cytomegalovirus disease. Michelson S, and Plotkin SA (Eds.). Exerpta Medica, Amsterdam, I993,pp. 241–249.Google Scholar
- 9.Snoeck R, Neyts J and De Clercq E: Strategies for the treatment of cytomegalovirus infections. In: Multidisciplinary approach to understanding cytomegalovirus disease. Michelson S, and Plotkin SA (Eds.). Excerpta Medica, Elsevier Science Publishers B.V. Amsterdam, 1993,pp. 269–278.Google Scholar
- 10.Haas M, Meijer DKF, Moolenaar F, De Jong PE and De Zeeuw D: Renal drug targeting: optimalisation of renal pharmacotherapeutics. In: International Yearbook of Nephrology 1996. Andreucci VE, and Fine LG (Eds.). Oxford University Press, 1996,pp. 3–11.Google Scholar
- 11.Mayer U, Wagenaar E, Beijnen JH, Smit JW, Meijer DKF, van Asperen J, Borst P, and Schinkel AH: Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdrla P-glycoprotein. Br J Pharmacol 1996; 119: 1038–1044.PubMedCrossRefGoogle Scholar
- 12.Kuipers ME, Huisman JO, Swart RI, de Bethune M-P, Pauwels R, De Clercq E, Schuitemaker H, and Meijer DKF: Mechanism of anti-HIV activity of negatively charged albumins: biomolecular interaction with the HIV-1 envelope protein gp120. J Acq Immun Defic Synd Hum R 1996; 11: 419–429.CrossRefGoogle Scholar
- 14.Miyoshi I, Taguchi H, Kubonishi I, Yoshimoto S, Ohtsuki Y, Shiraishi Y, and Akagi T: Type C virus-producing cell lines derived from adult T cell leukemia. Gann Monogr Cancer Res 1982; 28: 219–228.Google Scholar
- 17.Harmsen MC, Swart PJ, do Bethune M-P, Pauwels R, De Clercq E, The TH, and Meijer DKF: Antiviral effects of plasma and milk proteins: lactoferrin shows potent antiviral activity on both human immunodeficiency virus and human cytomegalovirus. J Infect Dis 1995; 172: 380–388.PubMedCrossRefGoogle Scholar
- 19.Swart PJ, and Meijer DKF: Negatively-charged albumins: A novel class of polyanionic proteins with a potent anti-HIV activity. Antiviral News 1994; 2: 69–70.Google Scholar
- 24.Gold P: Method of treatment of HIV-seropositive individuals with dietary whey proteins. 1994:1–18; PCT/CA93/00107 (Application number);WO 93/20831 (Patent number).Google Scholar
- 27.Lash JA, Coates TD. Lafuze J, Baehner RL, and Boxer LA: Plasma lactoferrin reflects granulocyte activation in vivo. Blood 1983;61:885–888.Google Scholar